Literature DB >> 28893433

Effects of remote ischemic preconditioning in patients with concentric myocardial hypertrophy: A randomized, controlled trial with molecular insights.

Young Song1, Jong Wook Song1, Sak Lee2, Ji-Hae Jun3, Young-Lan Kwak1, Jae-Kwang Shim4.   

Abstract

BACKGROUND: Efficacy of remote ischemic preconditioning (RIPC) for cardioprotection in cardiac surgery is controversial. We aimed to evaluate the clinical and molecular effects of RIPC on the concentrically hypertrophied myocardium.
METHODS: Seventy-two aortic stenosis patients receiving aortic valve replacement (AVR) under sevoflurane anesthesia were randomly allocated to RIPC (3cycles of 5-min inflation [300mmHg] and deflation on the left arm) or control (deflated cuff placement) group. The primary endpoints were 24-h area under the curve (AUC) for serum creatine kinase (CK)-MB and troponin (Tn)-T levels. The secondary endpoints were myocardial activation of cell signaling pathways, including reperfusion injury salvage kinases (RISK), signal transducer and activator of transcription (STAT), nitric oxide synthase (NOS), and apoptosis related molecules, obtained from right atrial tissue before and after cardiopulmonary bypass (CPB).
RESULTS: There were no intergroup differences in 24-h AUCs of CK-MB and Tn-T. Phosphorylations of RISK pathway molecules were not enhanced by RIPC before and after CPB. Phosphorylation of STAT5 was significantly lower in the RIPC group before and after CPB. Phosphorylations of STAT3 and endothelial NOS were not enhanced by RIPC before and after CPB. Expression level of cleaved caspases-3/caspase-3 was significantly higher in the RIPC group before CPB.
CONCLUSIONS: RIPC did not provide clinical benefits or activate protective signaling in patients with concentric left ventricular hypertrophy undergoing AVR.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiac enzyme; Cardiac surgery; Intracellular signaling; Left ventricular hypertrophy; Remote ischemic preconditioning

Mesh:

Substances:

Year:  2017        PMID: 28893433     DOI: 10.1016/j.ijcard.2017.08.073

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  Perioperative Cardioprotection by Remote Ischemic Conditioning.

Authors:  Youn Joung Cho; Won Ho Kim
Journal:  Int J Mol Sci       Date:  2019-09-29       Impact factor: 5.923

2.  Remote Ischemic Preconditioning to Prevent Acute Kidney Injury After Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Zigang Liu; Yongmei Zhao; Ming Lei; Guancong Zhao; Dongcheng Li; Rong Sun; Xian Liu
Journal:  Front Cardiovasc Med       Date:  2021-03-18

Review 3.  Regulation of STAT3 and its role in cardioprotection by conditioning: focus on non-genomic roles targeting mitochondrial function.

Authors:  Stefano Comità; Saveria Femmino; Cecilia Thairi; Giuseppe Alloatti; Kerstin Boengler; Pasquale Pagliaro; Claudia Penna
Journal:  Basic Res Cardiol       Date:  2021-10-12       Impact factor: 17.165

4.  Strategies for post-cardiac surgery acute kidney injury prevention: A network meta-analysis of randomized controlled trials.

Authors:  Jia-Jin Chen; Tao Han Lee; George Kuo; Yen-Ta Huang; Pei-Rung Chen; Shao-Wei Chen; Huang-Yu Yang; Hsiang-Hao Hsu; Ching-Chung Hsiao; Chia-Hung Yang; Cheng-Chia Lee; Yung-Chang Chen; Chih-Hsiang Chang
Journal:  Front Cardiovasc Med       Date:  2022-09-27

5.  The effect of remote ischemic preconditioning on serum creatinine in patients undergoing partial nephrectomy: a study protocol for a randomized controlled trial.

Authors:  Min Hur; Sun-Kyung Park; Jungho Shin; Jung-Yoon Choi; Seokha Yoo; Won Ho Kim; Jin-Tae Kim
Journal:  Trials       Date:  2018-09-04       Impact factor: 2.279

6.  Sevoflurane, Propofol and Carvedilol Block Myocardial Protection by Limb Remote Ischemic Preconditioning.

Authors:  Youn Joung Cho; Karam Nam; Tae Kyong Kim; Seong Woo Choi; Sung Joon Kim; Derek J Hausenloy; Yunseok Jeon
Journal:  Int J Mol Sci       Date:  2019-01-11       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.